noscript

News and Announcements

OncoSil Medical Interview on CE Mark and Growth Plans

  • Published November 26, 2015 12:31PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

26th November 2015, ASX Announcement

OncoSil Medical Limited (ASX:OSL) (OncoSil Medical, the Company) is pleased to provide details of an interview with Chief Executive Officer and Managing Director Daniel Kenny and Finance News Network  to discuss the Company’s CE Mark progress and growth plans.

The interview can be viewed via the OncoSil Medical company website; via this link: Media interview on CE Mark and Growth Plans 

OncoSil Medical is focused on the commercialisation of its lead product candidate, the OncoSilTM localised radiation treatment for cancer. It is concurrently seeking a Conformité Européenne (CE) Mark for OncoSilTM for pancreatic and primary liver cancer (HCC), which would facilitate commercialisation in the European Union and other major markets (including Australia, Canada and Singapore), and US approval via the US FDA.

The Company was granted a Fast Track review for its CE Mark with the European regulator in October this year and expects to receive the outcome of its CE Mark application in the near future.

To read the full announcement, please click here

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now